Celecoxib - Pfizer/Astellas Pharma

Drug Profile

Celecoxib - Pfizer/Astellas Pharma

Alternative Names: Celebra; Celebrex; Celecox; Niflam; Onsenal; SC-58635; YM-177

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Astellas Pharma; Dana-Farber Cancer Institute; Department of Veterans Affairs; Linkoping University Hospital; Pfizer; Swedish Lung Cancer Study Group; University of Connecticut; Zydus Cadila
  • Class Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute pain; Ankylosing spondylitis; Back pain; Cervicobrachial syndrome; Dental pain; Dysmenorrhoea; Familial adenomatous polyposis; Juvenile rheumatoid arthritis; Osteoarthritis; Pain; Periarthritis; Postoperative pain; Rheumatic disorders; Rheumatoid arthritis; Tendinitis; Tenosynovitis
  • Phase III Non-small cell lung cancer
  • Phase II Stomatitis
  • Discontinued Alzheimer's disease; Bladder cancer; Gouty arthritis; Prostate cancer

Most Recent Events

  • 01 Feb 2017 Pfizer terminates a phase I trial in Uveitis (In adolescents, In adults, In the elderly) due to difficulty in recruitment in USA (NCT02131012)
  • 13 Nov 2016 Top-line efficacy data from the phase IV PRECISION trial in Rheumatic arthritis released by Pfizer
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top